You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
美药厂Moderna就应对南非变种新冠新版本疫苗进行临床测试
阿思达克 02-25 10:54
美国药厂Moderna(MRNA.US)宣布,就应对新冠变种病毒株的新冠疫苗进行临床测试,有关疫苗将须经美国食品及药物管理局(FDA)审批方能使用。

据早前刊载的研究显示,接种目前疫苗人士当中,仅六分之一的抗体能应对南非变种的新冠病毒。公司因而决定进行两方面的测试,包括就原来疫苗加强剂量以提升抗体数目,及研发针对变种的疫苗。美国国家过敏及传染病中心将协助临床测试。公司已生产足够数量的测试疫苗。

辉瑞(PFE.US)与BioNTech(BNTX.US)、Novavax(NVAX.US)、强生(JNJ.US)及阿斯利康(AZN.US)与牛津大学的研究团队,均就变种病毒株研发新版本疫苗。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account